title: Inhibition of irritation and contact hypersensitivity by phenoxyacetic acid methyl ester in mice.
abstract: New anti-irritant treatments are required to prevent irritation and sensitization reactions to consumer medicines and dermatological drugs. We report here that phenoxyacetic acid methyl ester (PAME) is an effective agent to prevent and treat irritant and allergic contact dermatitis. Balb/c mice skin-treated with 1% PAME do not lose weight relative to vehicle-treated mice, nor is it irritating to mouse skin. Topical PAME prevents skin irritation to a wide variety of irritants including: arachidonic acid, capsaicin, sodium lauryl sulfate (SLS), disodium laureth sulfosuccinate and tetradecanoylphorbol-13-acetate. Histological studies showed that 1% PAME greatly diminished dermal neutrophilic infiltration and dermal capillary vessel dilation, and prevented epidermal hyperproliferation and hyperkeratosis that accompanies detergent (SLS)-induced skin irritation. Topical PAME inhibited ear swelling following ear challenge during the elicitation phase of contact hypersensitivity in mice sensitized with 1-chloro-2, 4-dinitrochlorobenzene (DNCB), oxazolone and the hair coloring dye rho-phenylenediamine (PPD). Finally, topical administration of 1% PAME prior to PPD or DNCB sensitization prevented the induction phase of contact hypersensitivity. These results indicate that PAME represents a potential new category of potent topical anti-inflammatory agents.
authors.affiliation: Bioderm Technologies Inc., Trenton, NJ 08608, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Wille
authors.forename: A
authors.initials: A
authors.lastname: Kydonieus
authors.forename: R S
authors.initials: RS
authors.lastname: Kalish
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017449:Dermatitis, Allergic Contact / Q000188:drug therapy* / Q000473:pathology; D004137:Dinitrochlorobenzene / Q000037:antagonists & inhibitors / Q000633:toxicity; D004231:Diuresis / Q000187:drug effects; D004431:Ear, External / Q000473:pathology; D005260:Female; D007509:Irritants / Q000037:antagonists & inhibitors* / Q000633:toxicity; D051379:Mice; D008807:Mice, Inbred BALB C; D010081:Oxazolone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000633:toxicity; D010648:Phenylacetates / Q000008:administration & dosage / Q000627:therapeutic use*; D010655:Phenylenediamines / Q000037:antagonists & inhibitors / Q000633:toxicity; D013501:Surface-Active Agents / Q000633:toxicity
chemical_list: D000893:Anti-Inflammatory Agents; D004137:Dinitrochlorobenzene; D007509:Irritants; D010648:Phenylacetates; D010655:Phenylenediamines; D013501:Surface-Active Agents; D010081:Oxazolone; C029728:4-phenylenediamine